Intratumoral CD4<sup>+</sup> T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32497499.
- Also identified by DOI 10.1016/j.cell.2020.05.017 and PMC identifier 7321885.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Responses to anti-PD-1 immunotherapy occur but are infrequent in bladder cancer. The specific T cells that mediate tumor rejection are unknown. T cells from human bladder tumors and non-malignant tissue were assessed with single-cell RNA and paired T cell receptor (TCR) sequencing of 30,604 T cells from 7 patients. We find that the states and repertoires of CD8<sup>+</sup> T cells are not distinct in tumors compared with non-malignant tissues. In contrast, single-cell analysis of CD4<sup>+</sup> T cells demonstrates several tumor-specific states, including multiple distinct states of regulatory T cells. Surprisingly, we also find multiple cytotoxic CD4<sup>+</sup> T cell states that are clonally expanded. These CD4<sup>+</sup> T cells can kill autologous tumors in an MHC class II-dependent fashion and are suppressed by regulatory T cells. Further, a gene signature of cytotoxic CD4<sup>+</sup> T cells in tumors predicts a clinical response in 244 metastatic bladder cancer patients treated with anti-PD-L1.
Medical subject headings
- CD4-Positive T-Lymphocytes
- Urinary Bladder Neoplasms